BookMark A. Geyer, Gerhard Gross, editors.
Summary: This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.
Contents:
Clinical instruments to evaluate and guide treatment in schizophrenia / Stephen R. Marder
Cognitive impairment in schizophrenia / Richard S. E. Keefe and Philip D. Harvey
Behavioral animal models to assess pro-cognitive treatments for schizophrenia / Jared W. Young, Nurith Amitai and Mark A. Geyer
Towards medication-enhancement of cognitive interventions in schizophrenia / Hsun-Hua Chou, Elizabeth Twamley and Neal R. Swerdlow
Mutant mouse models in evaluating novel approaches to antipsychotic treatment / Colm M. P. O'Tuathaigh, Lieve Desbonnet and John L. Waddington
5-HT2C agonists as therapeutics for the treatment of schizophrenia / Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross and John Dunlop
The role of dopamine D3 receptors in antipsychotic activity and cognitive functions / Gerhard Gross and Karla Drescher
Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the [alpha]7 nicotinic receptor / Ann Olincy and Robert Freedman
Muscarinic mechanisms in psychotic disorders / David L. McKinzie and Frank P. Bymaster
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications / Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu and Glenn Konopaske
Metabotropic glutamate receptors for new treatments in schizophrenia / E. J. Herman, M. Bubser, P. J. Conn and C. K. Jones
Glycine transport inhibitors in the treatment of schizophrenia / Daniel C. Javitt
Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia / Francine M. Benes
Development of disease-Modifying treatment of schizophrenia / Anton Bespalov, Corinna Klein, Berthold Behl, Gerhard Gross and Hans Schoemaker.